Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
10
pubmed:dateCreated
2011-9-9
pubmed:abstractText
Thrombomodulin (TM) is a predominantly endothelial transmembrane glycoprotein that modulates hemostatic function through a domain that controls thrombin-mediated proteolysis and an N-terminal lectin-like domain that controls inflammatory processes. To test the hypothesis that TM is a determinant of malignancy and dissect the importance of these functional domains in cancer biology, metastatic potential was evaluated in TM(Pro) mice expressing a mutant form of TM with reduced thrombin affinity and TM(LeD) mice lacking the N-terminal lectin-like domain. Studies of TM(Pro) mice revealed that TM is a powerful determinant of hematogenous metastasis. TM(Pro) mice exhibited a strongly prometastatic phenotype relative to control mice that was found to result from increased survival of tumor cells newly localized to the lung rather than any alteration in tumor growth. The impact of the TM(Pro) mutation on metastasis was dependent on both tumor cell-associated tissue factor and thrombin procoagulant function. In contrast, expression of a mutant form of TM lacking the lectin-like domain had no significant impact on metastasis. These studies directly demonstrate for the first time that TM-mediated regulation of tumor cell-driven procoagulant function strongly influences metastatic potential and suggest that endothelial cell-associated modulators of hemostasis may represent novel therapeutic targets in limiting tumor dissemination.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Sep
pubmed:issn
1528-0020
pubmed:author
pubmed:issnType
Electronic
pubmed:day
8
pubmed:volume
118
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
2889-95
pubmed:meshHeading
pubmed-meshheading:21788337-Animals, pubmed-meshheading:21788337-Carcinoma, Lewis Lung, pubmed-meshheading:21788337-Female, pubmed-meshheading:21788337-Hirudins, pubmed-meshheading:21788337-Humans, pubmed-meshheading:21788337-Lectins, pubmed-meshheading:21788337-Liver Neoplasms, pubmed-meshheading:21788337-Lung Neoplasms, pubmed-meshheading:21788337-Lymphatic Metastasis, pubmed-meshheading:21788337-Male, pubmed-meshheading:21788337-Melanoma, Experimental, pubmed-meshheading:21788337-Mice, pubmed-meshheading:21788337-Mice, Inbred C57BL, pubmed-meshheading:21788337-Mice, Transgenic, pubmed-meshheading:21788337-Mutation, pubmed-meshheading:21788337-Neoplastic Cells, Circulating, pubmed-meshheading:21788337-Oligonucleotides, Antisense, pubmed-meshheading:21788337-Platelet Count, pubmed-meshheading:21788337-Prothrombin, pubmed-meshheading:21788337-Recombinant Proteins, pubmed-meshheading:21788337-Sarcoma, Experimental, pubmed-meshheading:21788337-Thrombin, pubmed-meshheading:21788337-Thrombomodulin
pubmed:year
2011
pubmed:articleTitle
Thrombomodulin is a determinant of metastasis through a mechanism linked to the thrombin binding domain but not the lectin-like domain.
pubmed:affiliation
Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, USA.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't, Research Support, N.I.H., Extramural